Credit score: Haberdoedas Pictures from Pexels
Three new Cochrane evaluations discover proof that GLP-1 medicine end in clinically significant weight reduction, however industry-funded research elevate questions. The evaluations have been commissioned by the World Well being Group (WHO) to tell upcoming pointers on the usage of these medicine to deal with weight problems.
The evaluations, which look at the consequences of three weight reduction medicine referred to as GLP-1 receptor antagonists, have discovered that each one three medicine end in clinically significant weight reduction in contrast with placebo. Nevertheless, proof on longer-term outcomes, unintended effects, and potential conflicts of curiosity stays restricted or unsure.
Glucagon-like peptide-1 (GLP-1) receptor agonists have been initially developed to deal with folks with kind 2 diabetes, getting into medical use within the mid-2000s. In these sufferers, particularly these with coronary heart or kidney illness, the medicine improved blood sugar management, lowered the chance of coronary heart and kidney problems, supported weight reduction, and lowered the chance of early loss of life.
Extra not too long ago, GLP-1 receptor agonists have been trialed in folks with weight problems. The medicine mimic the exercise of a pure hormone that slows digestion and helps folks really feel full for longer. They’re presently licensed in the UK for weight administration alongside a lowered calorie food regimen and train in folks with weight problems, or people who find themselves chubby with weight-related well being issues.
GLP-1 medicine present promise for weight administration
Throughout the evaluations, tirzepatide, semaglutide, and liraglutide every led to vital weight reduction in comparison with placebo after one to 2 years, with these results prone to be sustained whereas therapy continues.
Tirzepatide (administered as soon as weekly) resulted in roughly a 16% weight discount after 12 to 18 months. Proof from eight randomized managed trials (6,361 contributors) additionally recommended these results might be maintained for as much as 3.5 years, though long-term security information have been restricted.
Semaglutide (additionally injected weekly) lowered physique weight by about 11% after 24 to 68 weeks, with results doubtless sustained as much as two years, drawing on 18 randomized managed trials (27,949 contributors). The drug elevated the probability of reaching a minimum of 5% physique weight reduction however was related to larger charges of mild-to-moderate gastrointestinal unintended effects.
Liraglutide (a day by day injection) resulted in a extra modest common weight discount of round 4%–5%, primarily based on 24 trials (9,937 contributors), however nonetheless elevated the proportion of individuals reaching significant weight reduction in contrast with placebo. Proof for longer-term results past two years was extra restricted.
Throughout the evaluations, there was little to no distinction between these medicine and placebo for main cardiovascular occasions, high quality of life, or mortality. Nevertheless, antagonistic occasions, significantly nausea and digestive signs, have been extra widespread amongst contributors taking GLP-1 medicine, and a few stopped therapy because of unintended effects.
“These drugs have the potential to bring about substantial weight loss, particularly in the first year,” says Juan Franco, co-lead researcher from Heinrich Heine College Düsseldorf, Germany. “It’s an exciting moment after decades of unsuccessful attempts to find effective treatments for people living with obesity.”
Impartial analysis and equitable entry are key
Most included research have been funded by the drug producers, who have been considerably concerned within the planning, conduct, evaluation, and reporting of the outcomes. This raises issues about potential conflicts of curiosity and the necessity for unbiased analysis.
The authors additionally emphasised that the broader use of those medicine ought to take into account social and business determinants of well being, together with entry, affordability and insurance coverage protection, to keep away from deepening present well being inequities amongst folks residing with weight problems. The excessive costs of semaglutide and tirzepatide presently restrict entry, whereas liraglutide’s expired patent has allowed for extra inexpensive generic variations to grow to be obtainable. Semaglutide’s patent may even expire in 2026.
Research included in all three evaluations have been performed primarily in middle- and high-income nations, with restricted or no illustration from areas corresponding to Africa, Central America, and Southeast Asia. Contemplating the variety in physique composition, food regimen, and well being behaviors throughout populations, the authors observe the significance of assessing how these medicine carry out in numerous world contexts.
“We need more data on the long-term effects and other outcomes related to cardiovascular health, particularly in lower-risk individuals,” says Eva Madrid, co-lead researcher from the Universidad de Valparaíso, Chile. “Weight regain after stopping treatment may affect the long-term sustainability of the observed benefits. More independent studies from a public health perspective are needed.”
The evaluations stress that unbiased, long-term investigations are important to tell medical and public coverage choices and to raised set up the position of GLP-1 receptor agonists in long-term weight administration.
Commissioned by the World Well being Group, these evaluations will inform forthcoming WHO pointers on the usage of GLP-1 receptor agonists for treating weight problems. The rules are anticipated to launch quickly, following a public session held in September.
Offered by
Cochrane
Quotation:
GLP-1 medicine efficient for weight reduction, however extra unbiased research wanted (2025, October 29)
retrieved 29 October 2025
from https://medicalxpress.com/information/2025-10-glp-drugs-effective-weight-loss.html
This doc is topic to copyright. Other than any honest dealing for the aim of personal research or analysis, no
half could also be reproduced with out the written permission. The content material is supplied for data functions solely.
